• First Berlin reiterated a Buy rating on Pharming Group, keeping a EUR 2.2 12-month target price.
• Update followed acceptance of an abstract on positive phase 2 leniolisib topline data for PI3KD-linked primary immunodeficiencies.
• Trial results showed improved lymphoproliferative disease, including a 26.4% mean spleen volume reduction.
• Safety profile matched prior experience; infections were most common, with no new safety signals flagged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EQS News (Ref. ID: rc_26886) on September 23, 2026, and is solely responsible for the information contained therein.